#USA #New York #Class Action #Levi Korsinsky #Zenas BioPharma

Class Action Alert for Zenas BioPharma Investors

Levi & Korsinsky, LLP has formally notified investors of Zenas BioPharma, Inc. (NASDAQ: ZBIO) regarding a pending class action lawsuit. This significant legal effort aims to secure compensation for shareholders affected by alleged securities fraud related to the company's initial public offering (IPO) in September 2024.

Nature of the Lawsuit

The class action is designed to represent those who acquired Zenas BioPharma shares that were affected by misinformation about the company’s financial status and operational viability. Specifically, the lawsuit claims that investors were led to believe that Zenas BioPharma could sustain its operations with existing cash reserves and the anticipated net proceeds from the IPO. However, it's alleged that the company's public statements were misleading and failed to accurately reflect its financial condition.

Key Details for Investors

The court has set a deadline of June 16, 2025, for investors wishing to be appointed as lead plaintiffs in this class action. It's important for those who suffered losses during the relevant time period to reach out as soon as possible to learn more and explore their options. Even if investors do not serve as lead plaintiffs, they may still qualify for compensation stemming from the outcome of this case.

If you purchased or otherwise acquired Zenas BioPharma securities in connection with the IPO, you can find out more information on how to join the case by following the link provided. Additionally, investors are urged to contact Joseph E. Levi, Esq. (.li) or call the law office directly for a consult regarding their legal options.

No Financial Risk to Investors

Participating in this class action comes at no cost to the investors involved. Class members can seek compensation without needing to pay any upfront out-of-pocket expenses or legal fees. This no-cost participation means that investors can pursue legal recourse without the financial burden often associated with litigation.

Levi & Korsinsky’s Track Record

Levi & Korsinsky has developed an outstanding reputation over two decades, successfully retrieving hundreds of millions of dollars for aggrieved shareholders. With a dedicated team of over 70 professionals, this firm specializes in complex securities litigation and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years by ISS Securities Class Action Services.

Take Action Now

Investors must recognize the importance of meeting the June deadline if they wish to participate in this class action suit against Zenas BioPharma. By taking timely action, you can help ensure your interests are represented and potentially claim compensatory damages for any losses incurred.

Should you require further assistance or have inquiries regarding the lawsuit, do not hesitate to reach out to Levi & Korsinsky at their New York office. The expertise and knowledge provided can be vital in navigating the complexities of securities litigation.

In conclusion, the Zenas BioPharma case serves as a reminder of the importance of transparency in the financial markets. Investors who believe they have been misled regarding a company's operations and financial health have the right and opportunity to seek justice through class action lawsuits. Stay informed, and take action to safeguard your investments.